Show simple item record

dc.contributor.authorLuo, Fanghongzh_CN
dc.contributor.authorLi, Yangzh_CN
dc.contributor.authorJia, Mengmengzh_CN
dc.contributor.authorCui, Feizh_CN
dc.contributor.authorWu, Hongjiezh_CN
dc.contributor.authorYu, Feizh_CN
dc.contributor.authorLin, Jinyazh_CN
dc.contributor.authorYang, Xiangruizh_CN
dc.contributor.authorHou, Zhenqingzh_CN
dc.contributor.authorZhang, Qiqingzh_CN
dc.contributor.author罗芳洪zh_CN
dc.contributor.author侯振清zh_CN
dc.contributor.author张其清zh_CN
dc.date.accessioned2015-07-22T07:37:30Z
dc.date.available2015-07-22T07:37:30Z
dc.date.issued2014zh_CN
dc.identifier.citationNanoscale Research Letters, 2014,9(1):1-13zh_CN
dc.identifier.issn1931-7573zh_CN
dc.identifier.other20143718154725zh_CN
dc.identifier.urihttps://dspace.xmu.edu.cn/handle/2288/93726
dc.description.abstractRecently, methotrexate (MTX) has been used to target to folate (FA) receptor-overexpressing cancer cells for targeted drug delivery. However, the systematic evaluation of MTX as a Janus-like agent has not been reported before. Here, we explored the validity of using MTX playing an early-phase cancer-specific targeting ligand cooperated with a late-phase therapeutic anticancer agent based on the PEGylated chitosan (CS) nanoparticles (NPs) as drug carriers. Some advantages of these nanoscaled drug delivery systems are as follows: (1) the NPs can ensure minimal premature release of MTX at off-target site to reduce the side effects to normal tissue; (2) MTX can function as a targeting ligand at target site prior to cellular uptake; and (3) once internalized by the target cell, the NPs can function as a prodrug formulation, releasing biologically active MTX inside the cells. The (MTX + PEG)-CS-NPs presented a sustained/proteases-mediated drug release. More importantly, compared with the PEG-CS-NPs and (FA + PEG)-CS-NPs, the (MTX + PEG)-CS-NPs showed a greater cellular uptake. Furthermore, the (MTX + PEG)-CS-NPs demonstrated a superior cytotoxicity compare to the free MTX. Our findings therefore validated that the MTX-loaded PEGylated CS-NPs can simultaneously target and treat FA receptor-overexpressing cancer cells. ? 2014 Luo et al.; licensee Springer.zh_CN
dc.language.isoen_USzh_CN
dc.publisherLuo et al.; licensee Springer.zh_CN
dc.source.urihttp://dx.doi.org/10.1186/1556-276X-9-363zh_CN
dc.subjectCellszh_CN
dc.subjectChitosanzh_CN
dc.subjectDrug deliveryzh_CN
dc.subjectLigandszh_CN
dc.subjectTumorszh_CN
dc.titleValidation of a Janus role of methotrexate-based PEGylated chitosan nanoparticles in vitrozh_CN
dc.typeArticlezh_CN


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record